Advertisement
U.S. markets open in 6 hours 21 minutes
  • S&P Futures

    5,080.75
    +0.50 (+0.01%)
     
  • Dow Futures

    39,119.00
    +3.00 (+0.01%)
     
  • Nasdaq Futures

    17,977.75
    +0.75 (+0.00%)
     
  • Russell 2000 Futures

    2,035.70
    +3.50 (+0.17%)
     
  • Crude Oil

    77.84
    +0.26 (+0.34%)
     
  • Gold

    2,045.10
    +6.20 (+0.30%)
     
  • Silver

    22.66
    +0.13 (+0.59%)
     
  • EUR/USD

    1.0857
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    4.2990
    0.0000 (0.00%)
     
  • Vix

    13.74
    0.00 (0.00%)
     
  • GBP/USD

    1.2688
    +0.0000 (+0.00%)
     
  • USD/JPY

    150.3230
    -0.3290 (-0.22%)
     
  • Bitcoin USD

    56,250.02
    +4,921.41 (+9.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,684.30
    0.00 (0.00%)
     
  • Nikkei 225

    39,239.52
    +5.81 (+0.01%)
     

Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M

Caribou Biosciences Inc (NASDAQ: CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).

Concurrently, Caribou priced an upsized underwritten public offering of 19.2 million shares at $6.50 per share, with gross proceeds of $125 million.

Last week, Caribou received an equity investment of $25 million from Pfizer Inc (NYSE: PFE) to advance CB-011 development.

The data set includes all 16 patients treated in dose escalation.

In ANTLER dose escalation, three dose levels of CB-010 were evaluated (40x106, 80x106, and 120x106 CAR-T cells) in patients with multiple subtypes of aggressive r/r B-NHL.

CB-010 was generally well tolerated with adverse events consistent with autologous or allogeneic anti-CD19 CAR-T cell therapies; as previously reported, no dose-limiting toxicities (DLTs) were observed at dose levels 2 or 3 following a single DLT at dose level 1.

A 94% overall response rate (ORR; 15 of 16 patients) was observed following a single dose of CB-010. 69% of patients (11 of 16) achieved a complete response (CR).

44% of patients (7 of 16) had a CR at ≥6 months; 24 months is the longest CR maintained to date.

For the subset of patients with large B cell lymphoma (LBCL) (N=10):

  • A 90% ORR (9 of 10) was observed.

  • 70% (7 of 10) achieved a CR.

  • 50% (5 of 10) had a CR at ≥6 months; 18 months is the longest CR maintained to date.

Caribou is enrolling second-line patients with LBCL in the ongoing dose expansion portion of the ANTLER clinical trial.

In expansion, the mid-dose and the high dose from escalation (80x106 and 120x106 CAR-T cells) are being evaluated in approximately 30 second-line patients to determine the recommended Phase 2 dose.

Caribou plans to report initial dose expansion data from the ongoing ANTLER trial in 1H 2024.

Price Action: CRBU shares are down 15.60% at $6.87 during the premarket session on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement